TR199902674T2 - Insanlarda bagisiklik eksilmesine sebep olan virüsün ve diger bulasici hastaliklarin antimikrobik vasitalarla önlenmesi ve tedavisi. - Google Patents

Insanlarda bagisiklik eksilmesine sebep olan virüsün ve diger bulasici hastaliklarin antimikrobik vasitalarla önlenmesi ve tedavisi.

Info

Publication number
TR199902674T2
TR199902674T2 TR1999/02674T TR9902674T TR199902674T2 TR 199902674 T2 TR199902674 T2 TR 199902674T2 TR 1999/02674 T TR1999/02674 T TR 1999/02674T TR 9902674 T TR9902674 T TR 9902674T TR 199902674 T2 TR199902674 T2 TR 199902674T2
Authority
TR
Turkey
Prior art keywords
drug
viruses
humans
prevention
treatment
Prior art date
Application number
TR1999/02674T
Other languages
English (en)
Inventor
Squires Meryl
Original Assignee
Squires Meryl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squires Meryl filed Critical Squires Meryl
Publication of TR199902674T2 publication Critical patent/TR199902674T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

HIV ve baska mikrobik enfeksiyonlarin çabuk ve güvenilir bir sekilde ortadan kaldirilmasi için iyilestirilmis bir tibbi tedavi ve ilaç saglanmaktadir. Pahali olmayan bu ilaci hastalar önceden belirlenen bir süreyle kendileri kullanabilmektedir. Ilaç mikrop inhibitörleri, pito-kimyasal maddeler ya da izolatlar içeren bir antimikrobik konsentrat ihtiva etmektedir. Tercihan ilaç bir surfaktan ve bir sulu tasiyici madde ya da çözücü ve bir besleyici madde de içermektedir. Tercih edilen biçiminde ilaç sunlari içermektedir: Echinacea ve Commiphora myrrha pito-kimyasal maddeleri, benzalkonyum klorür, bir steril sulu çözelti ve folik asit.
TR1999/02674T 1997-03-26 1998-03-24 Insanlarda bagisiklik eksilmesine sebep olan virüsün ve diger bulasici hastaliklarin antimikrobik vasitalarla önlenmesi ve tedavisi. TR199902674T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/824,041 US6350784B1 (en) 1996-02-12 1997-03-26 Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases

Publications (1)

Publication Number Publication Date
TR199902674T2 true TR199902674T2 (tr) 2000-02-21

Family

ID=25240459

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02674T TR199902674T2 (tr) 1997-03-26 1998-03-24 Insanlarda bagisiklik eksilmesine sebep olan virüsün ve diger bulasici hastaliklarin antimikrobik vasitalarla önlenmesi ve tedavisi.

Country Status (30)

Country Link
US (3) US6350784B1 (tr)
EP (1) EP0980203B1 (tr)
JP (2) JP2001527541A (tr)
KR (1) KR100403418B1 (tr)
CN (1) CN1258191A (tr)
AP (1) AP1163A (tr)
AT (1) ATE358418T1 (tr)
AU (1) AU727339B2 (tr)
BG (1) BG63612B1 (tr)
BR (1) BR9807892A (tr)
CA (1) CA2285394C (tr)
CZ (1) CZ298406B6 (tr)
DE (1) DE69837474T2 (tr)
DK (1) DK0980203T3 (tr)
EA (1) EA002423B1 (tr)
EE (1) EE9900436A (tr)
ES (1) ES2285765T3 (tr)
GE (1) GEP20022749B (tr)
HU (1) HU226910B1 (tr)
IL (1) IL132003A (tr)
IS (1) IS5191A (tr)
NO (1) NO325017B1 (tr)
NZ (1) NZ500002A (tr)
OA (1) OA11198A (tr)
PL (1) PL196036B1 (tr)
RS (1) RS49963B (tr)
SK (1) SK285810B6 (tr)
TR (1) TR199902674T2 (tr)
UA (1) UA65563C2 (tr)
WO (1) WO1998042188A1 (tr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350784B1 (en) * 1996-02-12 2002-02-26 Meryl J. Squires Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
US20090191288A1 (en) * 1996-02-12 2009-07-30 Squires Meryl J Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
US9662360B2 (en) 2008-10-09 2017-05-30 Meritus Corporation Treatment of herpes, pseudomonas, staph, and hepatitis
CA2368574C (en) 1999-03-26 2008-08-12 Sunstar Inc. Compositions for preventing and treating type i allergy
WO2001001947A1 (en) * 1999-06-30 2001-01-11 Unilever Plc Cosmetic skin care compositions containing cumic alcohol
AU6174900A (en) * 1999-07-08 2001-01-30 Patrick T. Prendergast Use of flavones, coumarins and related compounds to treat infections
US6759434B2 (en) 1999-09-22 2004-07-06 B. Ron Johnson Anti-infective compositions, methods and systems for treating disordered tissue
US6211243B1 (en) 1999-09-22 2001-04-03 B. Ron Johnson Methods for treating cold sores with anti-infective compositions
US8173709B2 (en) * 1999-09-22 2012-05-08 Quadex Pharmaceuticals, Llc Anti-infective methods for treating pathogen-induced disordered tissues
DE60003453T2 (de) * 1999-11-04 2004-04-15 Antoinette Maria Brandes Phytotherapeutische zubereitung
US7147859B2 (en) * 2000-05-15 2006-12-12 Laboratorios Biosintetica Ltda. Application of phytosterols (and their isomers), folic acid, cyanocobalamin and pyridoxin in dietetic (alimentary) fibers
ATE355071T1 (de) * 2000-06-19 2006-03-15 Skopichenko Dettwiler Victoria Kräuterzusammensetzung enthaltend calendula und eucalyptus für die behandlung und heilung von erkrankungen
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
IL143318A0 (en) * 2001-05-23 2002-04-21 Herbal Synthesis Corp Herbal compositions for the treatment of mucosal lesions
EP2545937A1 (en) * 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
US7923023B2 (en) * 2002-02-25 2011-04-12 Astech International LLC Method and composition for delivery of medicants to animals
CH696628A5 (de) * 2002-02-26 2007-08-31 Eprova Ag Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
US7115563B2 (en) 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
US8492443B2 (en) * 2002-07-08 2013-07-23 Joe S. Wilkins, Jr. Treatment for herpes simplex virus and other infectious diseases
FR2843125B1 (fr) * 2002-08-02 2012-11-16 Coletica Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs
EP2387883B2 (en) * 2002-08-12 2017-03-22 Lonza Inc. Antimicrobial compositions comprising sodium benzoate
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
IL153124A (en) * 2002-11-27 2010-06-30 Herbal Synthesis Corp Solid composition that can be glued to the lining
US20050036972A1 (en) * 2003-03-10 2005-02-17 Hy-Gene Biomedical Corporation System for managing pathogens and irritants and monitoring usage of anti-bacterial formulations
RU2234313C1 (ru) * 2003-06-04 2004-08-20 Кривошеин Юрий Семенович Средство инактивации коронавирусов
GB0326518D0 (en) * 2003-11-13 2003-12-17 Compton Developments Ltd Anti-cancer compounds
WO2005046695A1 (en) * 2003-11-17 2005-05-26 Maria Waithira Njuguna Injection vitamin b complex for treatment of non specific vaginitis (bacterial vaginitis)
US20080124408A1 (en) * 2004-07-07 2008-05-29 Mediherb Holdings Ltd. Echinacea Formulation
WO2006031230A1 (en) * 2004-09-10 2006-03-23 Hy-Gene Biomedical Corporation System for managing pathogens and irritants and monitoring usage of anti-bacterial formulations
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) * 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US20080038295A1 (en) * 2006-04-13 2008-02-14 Regents Of The University Of Michigan Compositions and methods for orthopox virus vaccination
JP2007332126A (ja) * 2006-06-16 2007-12-27 Teikyo Univ ヒトおよび愛玩動物のための抗白癬入浴剤
CN101697966B (zh) * 2007-01-08 2011-10-19 杭州民生药业有限公司 蓬莪术环二烯在制备治疗由病毒引起的疾病的药物中的应用
CN100594896C (zh) * 2007-01-08 2010-03-24 杭州民生药业有限公司 蓬莪术环二烯在制备治疗肿瘤疾病的药物中的应用
DE102007029042A1 (de) * 2007-06-21 2008-12-24 Analyticon Discovery Gmbh Pharmazeutische Zusammensetzung mit einem Trihydroxychromenone-Derivate
US8637094B2 (en) 2007-07-18 2014-01-28 Iraj E. Kiani Composition and method for treating viral conditions
US7700137B1 (en) 2007-07-18 2010-04-20 Kiani Iraj E Anti-viral compositions and method
US7850998B2 (en) * 2007-07-18 2010-12-14 Kiani Iraj E Method of treating viral conditions
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
EA201170239A1 (ru) 2008-07-22 2011-08-30 Айзун Фармасьютикалз, Инк. Противовоспалительная композиция для местного применения
CH699653B1 (de) * 2008-09-08 2010-05-14 Bioforce Ag Roggwil Tg Zubereitung zur Prävention und/oder Behandlung und/oder Verhinderung der Weiterverbreitung von Atemwegserkrankungen.
US20100204181A1 (en) * 2009-02-06 2010-08-12 Alcon Research, Ltd. N-halogenated amino acid formulations comprising phosphine or amine oxides
US20100303935A1 (en) * 2009-05-29 2010-12-02 Squires Meryl J Medicinal Composition
EP3020412B1 (en) * 2009-06-16 2017-10-11 The Regents of the University of Michigan An immunogenic composition comprising nanoemulsion inactivated rsv
EP2324840B1 (en) * 2009-11-18 2019-03-20 Croda Italiana S.p.A. Production of caffeoylquinic acids from plant cell cultures of echinacea angustifolia
WO2011082835A1 (en) * 2010-01-11 2011-07-14 Vitro-Bio Sarl New synergistic compositions for the treatment of topical viral infections
WO2011116220A2 (en) * 2010-03-17 2011-09-22 Arbonne International Llc Oral supplement
WO2012069605A1 (en) 2010-11-26 2012-05-31 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Novel e,e-diene compounds and their use as medicaments and cosmetics
US8287924B2 (en) 2011-03-17 2012-10-16 Sonia Pharma Gmbh Treatment of menopausal symptoms as novel indication for myrrh
DK2500026T3 (da) * 2011-03-17 2013-08-26 Sonia Pharma Gmbh Behandling af menopausale symptomer som moderne indikation for myrra
WO2012123539A1 (en) * 2011-03-17 2012-09-20 Sonia Pharma Gmbh Treatment of vaginal atrophy as novel indication for myrrh
KR101334348B1 (ko) * 2011-12-21 2013-11-29 한국생명공학연구원 바이러스 억제 활성을 갖는 플라보노이드 화합물
US9125911B2 (en) 2013-03-14 2015-09-08 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered tissues
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
US9549930B2 (en) 2013-03-14 2017-01-24 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered and/or prodromal stage tissue
ES2761429T3 (es) * 2013-04-17 2020-05-19 Global Health Solutions Ag Composición farmacéutica antiviral, que contiene un extracto de Juncus acutus
US10512664B2 (en) 2014-07-22 2019-12-24 Ralco Nutrition, Inc. Antiviral compositions and methods
CN106496202B (zh) * 2015-09-06 2019-08-06 中国海洋大学 一种生物碱类化合物及其制备方法与作为抗单纯疱疹ⅰ型病毒剂的应用
KR102670487B1 (ko) * 2016-11-17 2024-05-30 주식회사 엘지생활건강 시나린을 포함하는 구강질환 예방 또는 치료용 조성물
US12357584B2 (en) 2018-12-07 2025-07-15 Global Biolife Inc. Composition and method of controlling infectious diseases with functional fragrances
WO2020123559A1 (en) * 2018-12-11 2020-06-18 Glyciome, Llc Topical, isotonic compositions for genital use
KR102416208B1 (ko) * 2020-01-08 2022-07-01 건국대학교 산학협력단 발효된 선복화 추출물을 포함하는 항인플루엔자 바이러스용 조성물
PH12022551856A1 (en) 2020-01-22 2024-01-03 Seelos Therapeutics Inc Reducing side effects of nmda antagonists
KR102762400B1 (ko) * 2020-04-09 2025-02-06 권두한 항코로나바이러스능을 가지는 플라보노이드 배당체
IT202000018970A1 (it) * 2020-08-03 2022-02-03 Asoltech Srl Composizione a base di mirra
LU102656B1 (de) 2021-03-11 2022-09-12 Prosecur Gmbh Flüssiges Nahrungsergänzungsmittel zur Immunstimulation, Verfahren zu dessen Herstellung sowie Verwendung
CN115414349B (zh) * 2022-08-26 2023-11-03 武汉科前生物股份有限公司 芹菜素在制备治疗猫鼻支气管炎药物中的用途
KR102924378B1 (ko) 2022-12-01 2026-02-10 서울여자대학교 산학협력단 카페산을 포함하는 식물바이러스 방제용 조성물 및 이를 이용한 식물바이러스 방제 방법
KR102842849B1 (ko) * 2024-08-07 2025-08-06 알투이랩 주식회사 다재내성균을 포함한 다양한 균주 대상 살균력 및 장기간 지속 항균력을 갖는 복합 항균 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4283421A (en) * 1979-12-19 1981-08-11 Ray Frank F Anti-viral treatment
US4760079A (en) * 1983-01-10 1988-07-26 Baltech, Inc. Treatment of diseases caused by herpes viruses
US4935448A (en) * 1983-01-10 1990-06-19 Baldone Joseph A Treatment of diseases caused by herpes viruses
US4661354A (en) * 1984-06-21 1987-04-28 Finnerty Edmund F Topical treatment of herpes simplex with a zinc sulfate-camphor water solution
US4797420A (en) * 1984-08-14 1989-01-10 Jabco Manufacturing, Inc. Disinfectant formulation and method of use
US4585656A (en) * 1984-08-20 1986-04-29 Rosenthal Harold R Treatment of herpes
DE3521143A1 (de) * 1985-06-13 1986-12-18 Robugen Gmbh Arzneimittel zur behandlung schwerer herpes-infektionen
DE3522075A1 (de) * 1985-06-20 1987-01-02 Lomapharm Rudolf Lohman Gmbh K Sesquiterpenverbindungen, verfahren zu ihrer isolierung und arzneimittel, enthaltend diese verbindungen
EP0213099A3 (de) * 1985-08-23 1989-07-19 Cederroth Nordic Aktiebolag Mittel mit antiphlogistischer, immunstimulierender und zytoprotektiver Wirkung, ihre Herstellung und pharmazeutische Verwendungen
DE3533563A1 (de) * 1985-09-20 1987-03-26 Michael Birzer Mep-aids mittel
FR2620698B1 (fr) * 1987-09-23 1990-08-10 Atlantic Pharma Prod Fluorure d'ammonium quaternaire et son application dans une substance inhibitrice ou destructrice d'etres vivants unicellulaires
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
DE4017091A1 (de) 1990-05-27 1991-11-28 Walter Dr Mach Molekuelverbundsystem zur kontra-eskalativen therapie viraler infektionskrankheiten
US6348503B1 (en) * 1996-02-12 2002-02-19 Meryl J. Squires Method and topical treatment composition for herpesvirus hominis
US6355684B1 (en) * 1990-10-11 2002-03-12 Meryl J. Squires Antimicrobial treatment for herpes simplex virus and other infectious diseases
US6350784B1 (en) * 1996-02-12 2002-02-26 Meryl J. Squires Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
US5248503A (en) * 1992-01-03 1993-09-28 Emanuel King Rosalba Herbal dietary supplement
US5461029A (en) * 1992-04-24 1995-10-24 American Cyanamid Company Method of treating herpes viral infections using HBNF and MK proteins
US5455033A (en) * 1993-05-21 1995-10-03 Degree/Silverman M.D. Inc. Medicinal composition for treatment of inflammation
NL9500216A (nl) 1995-02-06 1996-09-02 Bio Pharma Sciences Bv Farmaceutische samenstelling voor de behandeling van herpes.
US5876728A (en) * 1995-02-15 1999-03-02 Howard David Kass Natural composition extracted from plants used in the treatment of cancer
AU679162B3 (en) * 1995-11-21 1997-06-19 Stolair Pty Ltd Therapeutic compositions

Also Published As

Publication number Publication date
EP0980203A1 (en) 2000-02-23
PL336168A1 (en) 2000-06-05
DE69837474T2 (de) 2007-12-13
SK131899A3 (en) 2000-12-11
BR9807892A (pt) 2000-02-22
US20060024393A1 (en) 2006-02-02
EA199900773A1 (ru) 2000-10-30
CZ336899A3 (cs) 2000-07-12
OA11198A (en) 2003-05-30
IS5191A (is) 1999-09-23
IL132003A (en) 2005-08-31
UA65563C2 (uk) 2004-04-15
EP0980203A4 (en) 2004-05-06
NO325017B1 (no) 2008-01-14
CA2285394C (en) 2013-01-08
IL132003A0 (en) 2001-03-19
CA2285394A1 (en) 1998-10-01
JP2000119188A (ja) 2000-04-25
AP1163A (en) 2003-06-30
EA002423B1 (ru) 2002-04-25
YU48099A (sh) 2002-03-18
DE69837474D1 (de) 2007-05-16
KR100403418B1 (ko) 2003-10-30
BG103786A (bg) 2000-10-31
GEP20022749B (en) 2002-08-26
SK285810B6 (sk) 2007-08-02
ES2285765T3 (es) 2007-11-16
US20030104082A1 (en) 2003-06-05
CZ298406B6 (cs) 2007-09-26
US6350784B1 (en) 2002-02-26
EE9900436A (et) 2000-04-17
HUP0001379A2 (hu) 2000-08-28
JP2001527541A (ja) 2001-12-25
DK0980203T3 (da) 2007-07-30
NO994639L (no) 1999-11-24
EP0980203B1 (en) 2007-04-04
NO994639D0 (no) 1999-09-24
CN1258191A (zh) 2000-06-28
BG63612B1 (bg) 2002-07-31
NZ500002A (en) 2001-09-28
US7071233B2 (en) 2006-07-04
AU6771898A (en) 1998-10-20
HUP0001379A3 (en) 2000-11-28
AP9901661A0 (en) 1999-09-30
RS49963B (sr) 2008-09-29
AU727339B2 (en) 2000-12-07
HU226910B1 (hu) 2010-03-01
PL196036B1 (pl) 2007-11-30
ATE358418T1 (de) 2007-04-15
WO1998042188A1 (en) 1998-10-01
KR20010005603A (ko) 2001-01-15

Similar Documents

Publication Publication Date Title
BG103786A (bg) Състав и метод за профилактика и лечение на нiv и други инфекциозни заболявания при човека
TR199802251T2 (tr) Herpes Simpleks virüsü ve diger enfeksiyonlu hastaliklar için antimikrobik tedavi için bilesimler.
HUP0002224A1 (hu) Virusellenes hatású benzimidazol-származékok
BR0017050A (pt) Oxazolidinonas suebstituìdas e seu emprego na área da coagulação do sangue
DE50206297D1 (de) Arzneimittel auf Basis von Gestagenen zur dermalen Anwendung enthaltend Ascorbinsäure sowie deren Salze
WO2001010468A3 (en) Drug-carrier complexes and methods of use thereof
ATE399562T1 (de) Verwendung von milchserum-apoproteinen bei der prophylaxe oder behandlung von mikrobiellen oder virusinfektionen
DE69322251D1 (de) Medizinische zusammensetzung
DE502004011851D1 (de) Caspase 3, 8, 9 oder 10 Inhibitoren in Kombination mit MEK Inhibitoren zur Behandlung von Influenza
TR200102024T2 (tr) Yeni tedavi.
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
DE68926972D1 (de) Thienotriazoldiazepinverbindungen und deren pharmazeutische Anwendungen
PT1350510E (pt) Utilizacao de um agente para suprimir a infeccao e proliferacao do virus da virus da sindrome de imunodeficiencia humana
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
NO954702L (no) Aryldannende medikamenter
FR2694693B1 (fr) Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
WO2004033479A3 (en) Retroyclins: antiviral and antimicrobial peptides
ATE454139T1 (de) Arzneimittel mit shikonin als wirkstoff
EP0601183A4 (en) ANTI-HIV MEDICINE.
Dangor et al. Treatment of chancroid
BR9809127A (pt) Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
BG100835A (bg) Ново лекарствено средство за лечение на вирусни инфекции на дихателните пътища
BR0008269A (pt) Uso de uma preparação de m. vaccae, e, método para tratamento de infecção viral crÈnica, excluindo infecção por hiv
Colvin Hemophilia and HIV standard of care
Scheibel Five-drug or six-drug antiretroviral therapy--conversation with Steven Scheibel, MD Interview by John S. James